Skip to navigation Skip to content

Non-small cell lung cancer (NSCLC) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051128

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised crizotinib, and entrectinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Non-small cell lung cancer (NSCLC) quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB156 form

Written

Electronic

S85
crizotinib
entrectinib

No

OPA

Not specified

Yes

Continuing

Telephone

Electronic

S85
crizotinib
entrectinib

No

OPA

Not specified

Yes